NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease
December 28, 2023 16:05 ET
|
NKGen Biotech, Inc.
NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1...
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
December 27, 2023 08:00 ET
|
NKGen Biotech, Inc.
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s...
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 14, 2023 16:48 ET
|
NKGen Biotech, Inc.
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase I/IIa by year end –...
NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 26, 2023 08:00 ET
|
NKGen Biotech, Inc.
90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks SNK01 given intravenously (IV) appears to cross...
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
October 24, 2023 08:00 ET
|
NKGen Biotech, Inc.
NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023 NKGen’s SNK01 program continues to show positive...
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 19, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
October 17, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
October 11, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Biotech, Inc. Announces Closing of Business Combination
October 02, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
NKGen Biotech to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
September 21, 2023 14:15 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...